Medicare Enrolled
Dr. James Myatt, MD
Cardiovascular Disease · Waco, TX
Practice pattern: Remote & Cardiac— Practice combining remote and cardiac services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Myatt from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Myatt? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Myatt
Dr. James Myatt is a cardiovascular disease in Waco, TX, with 18 years in practice. Based on federal Medicare data, Dr. Myatt performed 9,613 Medicare services across 4,041 unique beneficiaries.
Between the years covered by Open Payments, Dr. Myatt received a total of $40,093 from 64 pharmaceutical and/or device companies across 962 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Myatt is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 3% volume in TX$ $40,093 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,613
Medicare services
Top 3% in TX for cardiovascular disease
4,041
Unique beneficiaries
$79
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~534 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 2,780 | $0 | $2 |
| Office visit, established patient (30-39 min) | 825 | $92 | $296 |
| Regadenoson injection (Lexiscan) for heart stress test | 684 | $45 | $68 |
| Remote patient monitoring device, 30 days | 555 | $38 | $55 |
| Remote patient monitoring management, 20 min/month | 485 | $38 | $55 |
| Electrocardiogram (EKG), 12-lead | 437 | $11 | $52 |
| Echocardiogram, transthoracic | 415 | $139 | $478 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 258 | $20 | $64 |
| Office visit, established patient, complex (40-54 min) | 239 | $132 | $416 |
| Remote pacemaker monitoring, 90 days | 231 | $21 | $73 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 204 | $31 | $45 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 184 | $19 | $63 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 182 | $53 | $169 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 142 | $647 | $1,637 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 130 | $14 | $36 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 129 | $1,075 | $2,622 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 121 | $647 | $2,127 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 118 | $19 | $63 |
| Remote monitoring of pulmonary artery pressure sensor, up to 30 days | 81 | $38 | $121 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 81 | $29 | $89 |
| New patient office visit, complex (60-74 min) | 73 | $165 | $514 |
| Ultrasound of leg arteries or artery grafts | 68 | $178 | $589 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 65 | $27 | $69 |
| Hospital follow-up visit, high complexity | 63 | $93 | $205 |
| Remote pacemaker/defibrillator monitoring, 90 days | 56 | $17 | $57 |
| Ultrasonic guidance for blood vessel access | 54 | $11 | $31 |
| Ultrasound of both sides of head and neck blood flow | 53 | $140 | $466 |
| Cardiac catheterization | 50 | $178 | $590 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 47 | $43 | $144 |
| Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | 43 | $130 | $2,889 |
| Office visit, established patient (20-29 min) | 42 | $51 | $194 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 41 | $8 | $147 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $82 | $304 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 37 | $52 | $183 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 36 | $302 | $393 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 35 | $142 | $468 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 34 | $333 | $1,105 |
| Programming of dual lead pacemaker system | 33 | $61 | $190 |
| Initial hospital admission, high complexity | 31 | $136 | $383 |
| Injection, midazolam hydrochloride, per 1 mg | 30 | $0 | $2 |
| Telephone medical discussion with physician, 11-20 minutes | 28 | $57 | $222 |
| Complete ultrasound study of arm and leg arteries | 25 | $96 | $307 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 25 | $63 | $213 |
| Testing of autonomic (sympathetic) nervous system function | 25 | $96 | $302 |
| EKG interpretation and report | 23 | $6 | $21 |
| New patient office visit (45-59 min) | 23 | $120 | $378 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 21 | $192 | $987 |
| Evaluation of cardiac rhythm monitor system | 21 | $39 | $127 |
| Coagulation time measurement, activated | 19 | $4 | $60 |
| Coronary stent placement | 18 | $433 | $1,170 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 17 | $53 | $184 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $38 | $703 |
| Injection, fentanyl citrate, 0.1 mg | 16 | $1 | $8 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $397 | $1,030 |
| Review by radiologist of abdominal aorta and both leg arteries image | 15 | $73 | $190 |
| Review by radiologist of both arms or legs arteries image | 15 | $72 | $190 |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 15 | $479 | $1,310 |
| Programming of cardiac rhythm monitor system | 15 | $46 | $138 |
| Insertion of heart rhythm monitor under skin | 13 | $67 | $170 |
| Blood test, basic group of blood chemicals (calcium, ionized) | 13 | $13 | $125 |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 12 | $726 | $17,115 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 11 | $1,841 | $4,825 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.2% high complexity
42.7% medium
47.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$40,093
Total received (2018-2024)
Avg $5,728/year across 7 years
Top 13% in TX for cardiovascular disease
64
Companies
962
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$38,737 (96.6%)
Other
Charitable contributions, space rental, and other categories
$1,356 (3.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$8,645
2023$7,975
2022$6,466
2021$4,223
2020$3,802
2019$3,769
2018$5,214
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Medtronic, Inc.
$6,605
Penumbra, Inc.
$5,794
Abbott Laboratories
$5,487
BIOTRONIK INC.
$4,550
Medtronic Vascular, Inc.
$3,913
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$1,702
LANTHEUS MEDICAL IMAGING, INC.
$1,356
Novartis Pharmaceuticals Corporation
$1,131
Janssen Pharmaceuticals, Inc
$718
Edwards Lifesciences Corporation
$702
PFIZER INC.
$618
ABIOMED
$616
AstraZeneca Pharmaceuticals LP
$556
Inari Medical, Inc.
$506
E.R. Squibb & Sons, L.L.C.
$471
Novo Nordisk Inc
$461
Boehringer Ingelheim Pharmaceuticals, Inc.
$442
Boston Scientific Corporation
$438
Amgen Inc.
$413
Philips Electronics North America Corporation
$318
Amarin Pharma Inc.
$298
Tactile Systems Technology Inc
$270
Merck Sharp & Dohme LLC
$249
Impulse Dynamics (USA) Inc.
$222
ZOLL Respicardia, Inc.
$216
Gilead Sciences, Inc.
$161
Pfizer Inc.
$130
Kowa Pharmaceuticals America, Inc.
$130
ACIST MEDICAL SYSTEMS, INC.
$114
AngioDynamics, Inc.
$112
Merck Sharp & Dohme Corporation
$105
Vifor Pharma, Inc.
$95
Kiniksa Pharmaceuticals, Ltd.
$85
Alnylam Pharmaceuticals Inc.
$85
Esperion Therapeutics, Inc.
$82
Vital Connect, Inc
$79
SANOFI-AVENTIS U.S. LLC
$78
Pacira Pharmaceuticals Incorporated
$67
BOSTON SCIENTIFIC CORPORATION
$50
ARBOR PHARMACEUTICALS, INC.
$49
Actelion Pharmaceuticals US, Inc.
$46
Avinger Inc.
$45
Otsuka America Pharmaceutical, Inc.
$41
Kiniksa Pharmaceuticals International, plc
$39
Bayer HealthCare Pharmaceuticals Inc.
$38
ATRICURE, INC.
$37
Itamar Medical Inc
$35
Relypsa, Inc.
$34
Bard Peripheral Vascular, Inc.
$29
ConvaTec Inc.
$26
Digirad Corporation
$21
Nevro Corp.
$21
Regeneron Healthcare Solutions, Inc.
$21
Smith & Nephew, Inc.
$21
Acist Medical Systems, Inc.
$19
Lilly USA, LLC
$19
Philips North America LLC
$19
ShockWave Medical, Inc
$18
Corcept Therapeutics
$18
Astellas Pharma US Inc
$15
HEARTFLOW, INC.
$14
IDORSIA PHARMACEUTICALS US INC
$14
Cardiovascular Systems Inc.
$13
Lexicon Pharmaceuticals, Inc.
$13
Top 3 companies account for 44.6% of total payments
Associated products mentioned in payments ›
(4067) Tack Endovascular Systems BTK · (5027) Intact Vascular Und · (5050) Extended Holter · (6554) Peripheral Vascular Undivided · (6585) Omniwire · (AZ7) Lasers · ABRE · AMPLATZER TALISMAN · AMVIA EDGE · ANDEXXA · ASSURITY · ATRICLIP LAA EXCLUSION SYSTEM · AURYON LASER SYSTEM 100-120 VAC · AVEIR · AZURE XT DR MRI SURESCAN · Abre · Accent Pacemaker · Acticor · Acticor 7 VR-T DX · Arcalyst · Assurity Pacemaker · Azure · BELSOMRA · BIOMONITOR · BRILINTA · Benchmark · Bidil · BioMonitor · CAMZYOS · CARDIOMEMS · CHANTIX · CHOCOLATE PTA BALLOON CATHETER · CLOSUREFAST · COREVALVE EVOLUT R · Cardius 3m · Chocolate PTA Balloon · ClosureFast · Cobalt · Confirm Rx · CoreValve Evolut · Corlanor · DEFINITY · ELIQUIS · ENSITE · ENTRESTO · Edora · Edora 8 DR-T · Edwards SAPIEN 3 Transcatheter Heart Valve · Ellipse ICD · EverFlex · Exparel · FARXIGA · FFRct · FLEXITOUCH · FLOWTRIEVER CATHETER · Flexitouch Plus · Fortify Assura · General - Therapies · General - Vascular Intervention · HAWKONE · HD-IVUS · HawkOne · IN.PACT ADMIRAL · IN.PACT Admiral · INNOVAMATRIX AC · Image Guided Therapy Devices _ Peripheral · Impella · Indigo · Indigo System · Inpefa · JARDIANCE · JOT DX · Korlym · LATITUDE · LEQVIO · LEXISCAN · LINQ II · LifeVest · Livalo · MICRA · MULTAQ · Micra · NEXLETOL · ONPATTRO · ONYX FRONTIER · OPSUMIT · Optimizer · Optimizer Smart System · Optis Coronary Imaging System · Ozempic · PANTHERIS · PCI Optimization · PICO · PRADAXA · PRALUENT · Pacemakers · Penumbra Coil 400 · Penumbra System · Peripheral Orbital Atherectomy System · PressureWire FFR · QT Vascular Chocolate PTA Balloon · QUVIVIQ · RESOLUTE ONYX · RESONATE · RXi Systems · ReCross · Repatha · Resolute · Reveal LINQ · Rivacor · Rivacor 7 DR-T · RotarexS 6 F x 135 cm · Rybelsus · S · SAMSCA · SHOCKWAVE IVL SYSTEM WITH THE SHOCKWAVE C2 CORONARY IVL CATHETER · SQ RX PULSE GENERATOR · SQ-RX PULSE GENERATOR · SYNERGY · Saxenda · Senza · Solia · SpiderFX · THORATEC HEARTMATE 3 LVAS IMPLANT KIT · UPTRAVI · VERQUVO · VIGILANT · VITALPATCH RTM · Varithena Administration Pack · Vascepa · Veltassa · VenaSeal · Verquvo · WINREVAIR · WatchPAT · XARELTO · Xience Sierra Coronary Stent · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $417 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
18
Per 100K population
6.8
County median income
$63,888
Nearest hospital
ASCENSION PROVIDENCE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Myatt is a remote & cardiac specialist, with above-average Medicare volume (top 3% in TX), and high industry engagement (low-engagement, top 13%), with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Myatt experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Myatt performed 2,780 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Myatt receive payments from pharmaceutical companies?
Yes. Dr. Myatt received a total of $40,093 from 64 companies across 962 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Myatt's costs compare to other cardiovascular diseases in Waco?
Dr. Myatt's average Medicare payment per service is $79. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Myatt) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Waco
Browse cardiovascular diseases in Waco ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc..
By company
Penumbra, Inc. Payments to Doctors
See all physicians who received payments from Penumbra, Inc..
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology